Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
If you have questions, please contact your Fisher Phillips attorney, the authors of this Insight, any attorney in our Employee Benefits and Tax Practice Group
Lawsuits also allege that Novo Nordisk was not transparent about the safety of Ozempic
Like Professor Galloway, five months into this year, I concur that GLP-1s are playing a role at re-shaping not just American health care, but society as well.
Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
